Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04032899
Other study ID # P045
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 15, 2019
Est. completion date November 30, 2024

Study information

Verified date March 2024
Source Biosearch S.A.
Contact Juristo Fonollá, PhD
Phone +34618738539
Email Juristo.FonollaJoya@biosearchlife.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to evaluate the effect of consumption during pregnancy and the lactation period of the probiotic L. fermentum CECT5716 on the incidence of mastitis. Bacterial load and immunological parameters in breast milk, parameters related to breastfeeding as well as health parameters of the mother and baby will also be evaluated.


Description:

Pregnancy and lactation are important moments for the child that will determine their development and future health. One of the key processes is when the microbiota is established in the baby. Contamination during delivery with the mother's vaginal flora, as well as bacteria from the microbiota of breast milk, are important sources for intestinal colonization. However, the mother's microbiota can suffer alterations that affect the health of the mother and can also have an effect on the baby. Mastitis is a condition of the mammary gland that can affect between 3-30% of women during the period of lactation and is the first cause of abandonment of it. It is associated with a dysbiosis with the proliferation of microorganisms in milk such as Staphylococcus and Streptococcus. Previous studies carried out with the strain L. fermentum CECT5716 have demonstrated a powerful regulating activity of the microbiota of breast milk that translates into a preventive and curative effect on mastitis. The highest incidence of mastitis occurs during the first weeks after delivery, so the investigator's working hypothesis is that the modulation of the maternal microbiota before delivery would improve the effectiveness of the probiotic strain consumption.


Recruitment information / eligibility

Status Recruiting
Enrollment 480
Est. completion date November 30, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Normal development of pregnancy - Single fetus pregnancy - Be in week 28-32 of pregnancy - Intention to breastfeed the child for 16 weeks Exclusion Criteria: - Having a breast disease that hinders or prevents breastfeeding - Have been taking probiotic supplements 2 weeks before starting the study - Have a low expectation of adherence to the study protocol

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Lactobacillus fermentum CECT5716
Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
Maltodextrin
Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.

Locations

Country Name City State
Spain Hospital Campus de la Salud Granada Grabada
Spain Hospital Virgen de las Nieves Granada
Spain Hospital Costa del Sol Marbella Andalucia

Sponsors (1)

Lead Sponsor Collaborator
Biosearch S.A.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Recurrence of mastitis Reappearance of mastitis symptoms 4 months
Other Breast pain questionnaire Mcgill Pain Questionnaire, validated for Spain. The Questionnaire has four dimensions or scales of measures of intensity: Sensory Intensity Value, Affective Intensity Value, Current Intensity Value, and Evaluative Intensity Value. The scales of the Questionnaire were calculated as the sum of their items. Those items were re-corded as 1 if the participant described the pain or as 0 if the participant did not report that type of pain. Thus, the sensory intensity scale can range from 0 to 33, as the full scale is formed by 33 items. The Affective scale varies from 0 to 19, and the scales of Current Intensity and Evaluative Intensity can range from 0 to 6 and 5, respectively 4 months
Other Time of Breastfeeding Date of initiation and cessation of breastfeeding 4 months
Other Percentage of infants breastfeed Percentage of infants who receive exclusive breastfeeding 4 months
Other Measurement of biomarkers of inflammation in breast milk Concentration of IL-1b, IL-6, IL-8, IL-17, TNF-a in breast milk 4 months
Other Immunoglobulins in breast milk Concentration of IgA, IgG1, IgG2, IgG3, IgG4 and IgM in breast milk 4 months
Other Minerals in breast milk Concentration of calcium (µg/L), magnesium (µg/L) and potassium (µg/L) in breast milk 4 months
Other Baby feces microbiota Presence of Escherichia coli, Clostridium, Bacteroides, Bifidobacteria, Lactobacillus and L. fermentum CECT5716 in baby feces 4 months
Other Data on childbirth Incidence of cesareans and incidence of antibiotic use during delivery. 4 months
Other Baby's anthropometric measures Anthropometric measures of the baby (weight in kg, height in cm and BMI in kg/m2) at birth, 4 weeks, 8 weeks and 16 weeks. 16 weeks
Other Data about the intestinal health of the baby Data about stool frequency, colour and consistency of the feces and gasses 4 months
Other Data about sleep parameters of the baby Hours of night sleeping per day and hours of total sleeping during the day 4 months
Primary Incidence of mastitis Total events during breastfeeding period /total number of participants 4 months
Secondary Microbiota of breast milk Load of Staphylococcus, S. aureus, S. epidermidis, Streptococcus, Lactobacillus and L. fermentum CECT5716 in breast milk 4 months
See also
  Status Clinical Trial Phase
Completed NCT02542527 - Evaluation of the Functionality of a Fluid Filled Single Breast Pump N/A
Terminated NCT02755194 - "Drugs in Lactation" Analysis Consortium
Terminated NCT00851591 - Effect of Fenugreek on Milk Production N/A
Withdrawn NCT00181649 - Recombinant Human Prolactin for Lactation Induction Phase 2
Completed NCT00181610 - Recombinant Human Prolactin for Lactation Induction Phase 2
Completed NCT04024865 - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Terminated NCT02378233 - Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant N/A
Recruiting NCT06203444 - An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females Phase 1
Completed NCT01747668 - Lactation Fortification Study Phase 3
Completed NCT02621827 - Vitamin D Half-life in Pregnancy and Lactation N/A
Completed NCT01463202 - Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression Phase 4
Terminated NCT04146909 - The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women N/A
Completed NCT04593719 - Effect of Lactation Management Model on Breastfeeding Process N/A
Completed NCT01548313 - The Role of Human Milk in Development of Breast Fed Child's Intestinal Microbiota
Completed NCT02690675 - Iron Supplement Effect on Child Development N/A
Completed NCT05123183 - Nonpharmacological Methods and Lactation N/A
Completed NCT03091985 - Influence of the Brownie Breast Shield on the Dynamics of Milk Removal N/A
Completed NCT02190448 - Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation N/A
Not yet recruiting NCT06264349 - Women and Maternity: Development of a Nutritional Education Project N/A
Recruiting NCT02384655 - Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content Phase 1/Phase 2